NDAORALCAPSULEPriority Review
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
0/100
Mechanism of Action
(ClpP). Dordaviprone also inhibits the dopamine D2 receptor. Diffuse midline gliomas harboring an H3 K27M mutation are associated with the loss of H3 K27 trimethylation. In-vitro, dordaviprone activated the integrated stress response, induced apoptosis, and altered mitochondrial metabolism leading…
Loss of Exclusivity
LOE Date
Jan 30, 2037
132 months away
Patent Expiry
Jan 30, 2037
Exclusivity Expiry
Aug 6, 2030
Company
Chimerix
NC - Durham